All In Biotech

Drug Trial Radar · NCT02032823

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

Last checked: Nov 19, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,837 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,837

Actual

Start

Apr 22, 2014

Primary completion

Mar 27, 2020

Study completion May 28, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Frontier Science & Technology Research Foundation, Inc.; NRG Oncology; Myriad Genetic Laboratories, Inc.; The Breast Adjuvant Study Team; Merck Sharp & Dohme LLC
First posted
Jan 10, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy

Conditions

  • Breast Cancer

Interventions

  • OlaparibDrug

    Patients will be administred olaparib orally twice daily (b.i.d.) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 ml of water

  • PlaceboDrug

    Patients will be administred matching placebo. Two (2) tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 ml of water

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive Disease Free Survival (IDFS)Time frame: From date of randomisation to data cut off: 27 March 2020 (approximately 5 years 11 months)

Locations

698 sites in 24 countries. Site status is shown where the registry gives one.

  • Research Site

    Anchorage, Alabama

  • Research Site

    Anchorage, Alaska

  • Research Site

    Gilbert, Arizona

  • Research Site

    Fort Smith, Arkansas

  • Research Site

    Baldwin Park, California

  • Research Site

    Berkeley, California

  • Research Site

    Duarte, California

  • Research Site

    Fontana, California

  • Research Site

    Fresno, California

  • Research Site

    Greenbrae, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Martinez, California

  • Research Site

    Newport Beach, California

  • Research Site

    Oakland, California

  • Research Site

    Palo Alto, California

  • Research Site

    Paradise, California

  • Research Site

    Roseville, California

  • Research Site

    Roseville, California

  • Research Site

    Sacramento, California

  • Research Site

    San Francisco, California

  • Research Site

    San Jose, California

  • Research Site

    San Leandro, California

  • Research Site

    San Marcos, California

  • Research Site

    Santa Cruz, California

  • Research Site

    Santa Rosa, California

  • Research Site

    South San Francisco, California

  • Research Site

    Stockton, California

  • Research Site

    Sunnyvale, California

  • Research Site

    Sunnyvale, California

  • Research Site

    Vacaville, California

  • Research Site

    Vallejo, California

  • Research Site

    Woodland Hills, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Denver, Colorado

  • Research Site

    Edwards, Colorado

  • Research Site

    Fort Collins, Colorado

Showing 40 of 698 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.